Research programme: T cell inhibitors - Cour Pharmaceutical Development Company

Drug Profile

Research programme: T cell inhibitors - Cour Pharmaceutical Development Company

Alternative Names: Cour-NP-GLI; TIMP/Gliadin; Toleragenic Immune Modifying nanoParticles - coeliac disease; Tolerising Immune Modifying nanoParticles - coeliac disease; Tolerizing Immune Modifying nanoParticles - coeliac disease

Latest Information Update: 21 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cour Pharmaceutical Development
  • Developer Cour Pharmaceutical Development; University of Helsinki
  • Class Polymers; Proteins
  • Mechanism of Action Gliadin inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Coeliac disease
  • Research Type 1 diabetes mellitus

Most Recent Events

  • 01 Nov 2013 Cour Pharma enters into option and evaluation alliances with two undisclosed pharmaceutical companies for development of products in Coeliac disease and Type-1 diabetes mellitus
  • 01 Nov 2013 Early research in Type-1 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top